Shares of Bayer AG jumped 6 percent after a federal judge in Minneapolis denied a motion to certify a nationwide class action lawsuit against the company regarding its now-withdrawn cholesterol-lowering therapy Baycol (cerivastatin). The judge ruled in favor of Bayer after the company argued that certification of a class action suit “was not appropriate because the claims of the possible class members involve too many diverse and individual issues,” Bayer said.
Posted by Editor at September 25, 2003 10:28 AM